The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | MPN highlights from EHA 2016
Srdan Verstovsek, MD, PhD of the University of Texas MD Anderson Cancer Center, Houston, TX discusses highlights in myeloproliferative neoplasm (MPN) research at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. As the EHA meeting is becoming more popular, more sessions on MPN are run. The sessions on the biology are dissecting the cause of hyperactive JAK/STAT pathway, which is abnormal in MPN patients. Further, he talks about prognostication, i.e. understanding these mutations and their effect. In terms of clinical studies, he highlights the RESPONSE-2 (NCT02038036) that was complementary to an earlier study that led to the approval of ruxolitinib, a JAK inhibitor, for polycythemia vera (PV) in second-line.
